{"id":"tegoprazan-50-mg","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Headache","drugRate":"10%","severity":"Mild"},{"effect":"Diarrhea","drugRate":"8%","severity":"Mild"},{"effect":"Nausea","drugRate":"5%","severity":"Mild"},{"effect":"Dizziness","drugRate":"3%","severity":"Mild"},{"effect":"Constipation","drugRate":"2%","severity":"Mild"}],"contraindications":[],"specialPopulations":{}},"trials":[],"_chembl":null,"aliases":["K-CAB","K-cab"],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2020-01-01","type":"Clinical","milestone":"Phase III Clinical Trials Completed","regulator":"NMPA"},{"date":"2021-06-01","type":"Regulatory","milestone":"Marketing Authorization Application Submitted","regulator":"NMPA"},{"date":"2022-03-01","type":"Regulatory","milestone":"Marketing Authorization Granted","regulator":"NMPA"}],"_dailymed":null,"aiSummary":"Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by the First People's Hospital of Hangzhou. It is designed to inhibit gastric acid secretion more effectively and rapidly than traditional proton pump inhibitors (PPIs). Tegoprazan has shown promise in treating gastroesophageal reflux disease (GERD) and peptic ulcers, with clinical trials demonstrating its efficacy and safety. However, it does not have an FDA label, indicating that it may be approved or used in other regions. The drug's mechanism of action involves competitive inhibition of the H+/K+-ATPase enzyme, which is responsible for acid production in the stomach. Tegoprazan's rapid onset of action and sustained effect make it a potential alternative to existing treatments.","ecosystem":[],"mechanism":{"target":"H+/K+-ATPase","novelty":"Tegoprazan represents a new class of acid suppressants that offer a faster onset of action and potentially fewer side effects compared to traditional PPIs.","modality":"Oral","drugClass":"Potassium-Competitive Acid Blocker (P-CAB)","explanation":"Tegoprazan competes with potassium ions for binding to the H+/K+-ATPase enzyme, which is located on the luminal surface of parietal cells in the stomach. This competitive inhibition prevents the exchange of hydrogen ions for potassium ions, thereby reducing the secretion of gastric acid.","oneSentence":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion.","technicalDetail":"The H+/K+-ATPase enzyme is a key target for acid suppression. Tegoprazan binds to the enzyme with high affinity and reversibly, leading to a rapid and sustained reduction in gastric acid secretion. Unlike proton pump inhibitors (PPIs), which irreversibly inhibit the enzyme, P-CABs like Tegoprazan can quickly dissociate from the enzyme, allowing for faster recovery of acid secretion when needed."},"_scrapedAt":"2026-03-28T00:11:32.872Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":null,"launchDate":null,"annualCostUS":null,"currentRevenue":null,"patientPopulation":null,"peakSalesEstimate":null},"references":[],"biosimilars":[],"competitors":["Esomeprazole (Nexium)","Lansoprazole (Prevacid)","Pantoprazole (Protonix)","Rabeprazole (Aciphex)"],"indications":{"approved":["Gastroesophageal Reflux Disease (GERD)","Peptic Ulcer"],"offLabel":[],"pipeline":["Erosive Esophagitis","Helicobacter pylori Eradication"]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06977841","phase":"NA","title":"Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2025-06-10","conditions":"Helicobacter Pylori Eradication, Adverse Reaction","enrollment":640},{"nctId":"NCT06340334","phase":"NA","title":"Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-03-31","conditions":"Helicobacter Pylori Infection, Tegoprazan, Furazolidone","enrollment":400},{"nctId":"NCT05647278","phase":"PHASE4","title":"Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)","status":"COMPLETED","sponsor":"Zhang Xiaofeng,MD","startDate":"2023-11-01","conditions":"Helicobacter Pylori Infection","enrollment":370},{"nctId":"NCT04416581","phase":"PHASE4","title":"Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy","status":"RECRUITING","sponsor":"Duk-Woo Park, MD","startDate":"2021-05-12","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome","enrollment":3320},{"nctId":"NCT07242456","phase":"PHASE2, PHASE3","title":"Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication","status":"RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2025-02-17","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT07242443","phase":"PHASE4","title":"Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）","status":"NOT_YET_RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2025-11-20","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":240},{"nctId":"NCT06743243","phase":"PHASE4","title":"Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia","status":"ENROLLING_BY_INVITATION","sponsor":"Seok Kyeong Oh","startDate":"2025-07-23","conditions":"General Anesthesia","enrollment":174},{"nctId":"NCT06991348","phase":"PHASE4","title":"Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole","status":"RECRUITING","sponsor":"Carnot Laboratories","startDate":"2024-07-30","conditions":"Gastroesophageal Reflux Disease","enrollment":128},{"nctId":"NCT06523764","phase":"PHASE4","title":"Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-11-11","conditions":"Helicobacter Pylori Infection Chronic Gastrit","enrollment":208},{"nctId":"NCT06894992","phase":"NA","title":"Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment","status":"RECRUITING","sponsor":"Mario Steffanus","startDate":"2025-05-01","conditions":"Peptic Ulcer Bleeding","enrollment":162},{"nctId":"NCT06431737","phase":"","title":"Comparison of Twice- and Four-times-daily Amoxicillin Administration in 2-week Tegoprazan-based H. Pylori Eradication","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2024-04-01","conditions":"H.Pylori Infection","enrollment":100},{"nctId":"NCT06682533","phase":"","title":"Tegoprazan- Versus PPI-based H. Pylori Eradication","status":"RECRUITING","sponsor":"Soonchunhyang University Hospital","startDate":"2024-12-01","conditions":"H.Pylori Infection","enrollment":200},{"nctId":"NCT06382493","phase":"NA","title":"Tegoprazan-containing Sequential for H. Pylori","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2021-02-01","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT06318104","phase":"PHASE4","title":"Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole","status":"NOT_YET_RECRUITING","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2024-04-19","conditions":"Helicobacter Pylori Infection","enrollment":160},{"nctId":"NCT05723510","phase":"PHASE1","title":"PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2023-03-06","conditions":"Healthy","enrollment":87},{"nctId":"NCT05453994","phase":"","title":"Bismuth for PCAB-based H. Pylori Eradication","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2020-03-01","conditions":"H. Pylori Infection","enrollment":150},{"nctId":"NCT05933031","phase":"PHASE2","title":"Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-02-27","conditions":"Helicobacter Pylori Infection","enrollment":381},{"nctId":"NCT05915871","phase":"PHASE1","title":"Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2023-03-23","conditions":"Healthy","enrollment":22},{"nctId":"NCT05786807","phase":"PHASE4","title":"Effect of H. Pylori Eradication on Alleviating Symptoms in Functional Dyspepsia Patients","status":"UNKNOWN","sponsor":"Wonkwang University Hospital","startDate":"2022-03-07","conditions":"Helicobacter Pylori-positive With Functional Dyspepsia","enrollment":315},{"nctId":"NCT04674774","phase":"NA","title":"Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Incheon St.Mary's Hospital","startDate":"2021-03-04","conditions":"Helicobacter Pylori Infection","enrollment":217},{"nctId":"NCT04568772","phase":"PHASE1","title":"Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-11-25","conditions":"Gastroesophageal Reflux Disease","enrollment":19},{"nctId":"NCT04128917","phase":"PHASE3","title":"Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-01-21","conditions":"Helicobacter Pylori Infection","enrollment":102},{"nctId":"NCT04221321","phase":"PHASE1","title":"Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-01-07","conditions":"Healthy","enrollment":32},{"nctId":"NCT04231136","phase":"PHASE1","title":"Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-01-14","conditions":"Healthy","enrollment":19},{"nctId":"NCT04639804","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-06-06","conditions":"Healthy","enrollment":60},{"nctId":"NCT03498456","phase":"PHASE3","title":"Triple Therapy With Tegoprazan in H. Pylori Positive Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2018-06-28","conditions":"Helicobacter Pylori Infection","enrollment":284},{"nctId":"NCT04171687","phase":"PHASE1","title":"Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-10-21","conditions":"Healthy","enrollment":36},{"nctId":"NCT03814642","phase":"PHASE1","title":"Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-01-21","conditions":"Healthy","enrollment":25},{"nctId":"NCT04066257","phase":"PHASE1","title":"Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-01-17","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":38,"therapeuticAreas":["Gastroenterology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Tegoprazan 50 mg","genericName":"Tegoprazan 50 mg","companyName":"First People's Hospital of Hangzhou","companyId":"first-people-s-hospital-of-hangzhou","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":6,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}